Table 1 Clinical characteristics and treatment response of all patients

N (%)

48

29

19

Age (year) -mean ± SD

64.6 ± 8.9

67.3 ± 8.0

60.6 ± 8.8

Age -n (%)

  < 65 years old

26 (54%)

12 (41%)

14 (74%)

  ≥ 65 years old

22 (46%)

17 (59%)

5 (26%)

Sex -n (%)

 Female

30 (63%)

23 (79%)

7 (37%)

 Male

18 (38%)

6 (21%)

12 (63%)

Smoking history -n (%)

 Never smoker

43 (90%)

28 (97%)

15 (79%)

 Ever smoker

5 (10%)

1 (3%)

4 (21%)

TTF-1 staining -n (%)

 Positive

47 (98%)

29 (100%)

18 (95%)

 Not performed

1 (2%)

0 (0%)

1 (5%)

EGFR gene mutation site -n (%)

 Exon19

29 (60%)

19 (66%)

10 (53%)

 Exon21

19 (40%)

10 (34%)

9 (47%)

Performance status while starting afatinib -n (%)

 ECOG ≤1

38 (79%)

22 (76%)

16 (84%)

 ECOG ≥2

10 (21%)

7 (24%)

3 (16%)

Number of metastatic sites on initial diagnosis -n (%)

  ≤ 1 site

21 (44%)

15 (52%)

6 (32%)

  ≥ 2 sites

27 (56%)

14 (48%)

13 (68%)

Metastatic sites on initial diagnosis -n (%)

 Brain metastasis

12 (25%)

8 (28%)

4 (21%)

 Lung metastasis

14 (29%)

6 (21%)

8 (42%)

 Pleural metastasis/pleural effusion

21 (44%)

12 (41%)

9 (47%)

 Bone metastasis

28 (58%)

17 (59%)

11 (58%)

 Liver metastasis

2 (4%)

1 (3%)

1 (5%)

 Adrenal metastasis

7 (15%)

3 (10%)

4 (21%)

Weight (kg) -mean ± SD

58.1 ± 9

55.4 ± 9.3

62.2 ± 6.8

Height (cm) -mean ± SD

158.9 ± 7.9

156.8 ± 7.6

162.0 ± 7.6

Body surface area (m²) -mean ± SD

1.6 ± 0.2

1.5 ± 0.2

1.7 ± 0.1

Body mass index (kg/m²) -mean ± SD

23.0 ± 2.9

22.5 ± 3.4

23.7 ± 1.9

Serum creatinine level (mg/dL) -mean ± SD

1.1 ± 1.9

1.0 ± 1.7

1.3 ± 2.2

eCCr-CG (mL/min) -mean ± SD

74.6 ± 28.4

69.8 ± 25.3

82.1 ± 31.7

eGFR-MDRD (mL/min) -mean ± SD

89.9 ± 31.4

89.5 ± 29.7

90.5 ± 34.6

Serum albumin (mg/dL)

3.9 ± 0.6

3.8 ± 0.6

4.1 ± 0.5